Sponlor. Lupin Inc. 
ProCoGol no: TB-OPI-301 
1.0 Appro 'C.'s 
Spoaor: Lupla lac. 
Repraeotativel Title: 
Slpat11re !Date: 
Representative/ Title: 
Signatare !Date: 
PRA 
Project 
Maugermtte: 
Sipature /Date: 
8101tadlticiao I Title 
(Owner): 
Sigaature /Date: 
 -� Lupin Inc. 
TB-DPI-301 
LPBTB30 1-TB30 I X 
11-May-2017 
Amendment I ,. . . -la:: St8tilticlll � PWt 
Veillon oate:F"IMI 01Feb2018 
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover, 
Multicenter Clinical Study to Assess the Efficacy and Safety of Once Daily 
Administration of Lupin Tiotropiurn Bromide Inhalation Powder Compared to 
SPIRIV A® HANDIHALER® and Placebo in Patients with COPD including a 
12-Week Open-Label Extension to Assess Inhaler Robustness 
14-Mar-201 7 
SAP2 Final / 08Feb20 18 
velopment Inhalation, Complex Generics, and Brands 
/ 
 
 
(Original aut/ror; XID 
MD I Semor BIOIIaiUiiciOII) 
 O�R-�18 
P.1 of 52 
Strictly Confidential. C 2004-2015,  All rights reserved. Page 1 of 49

Statistical Analysis Plan
Version Date:Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB-DPI-301
Page 2 of 49
Strictly Confidential.  © 2004-2015, .  All rights reserved.
Table of Contents
Approvals...................................................................................................................... ....................................................................... 1
Table of Contents.............................................................................................................. ................................................................ 2
Purpose........................................................................................................................ ......................................................................... 4
Scope.......................................................................................................................... ............................................................................ 4
Introduction................................................................................................................... ..................................................................... 4
Study Objectives ............................................................................................................... ................................................................ 4
Study Design................................................................................................................... .................................................................... 5
7.1 Sample Size Co nsiderations ................................................................................................. ................................................ 17
7.2 Randomization .............................................................................................................. ............................................................ 18
Study Variables................................................................................................................ ............................................................... 18
8.1 Primary Effica cy Variable.................................................................................................. .................................................... 18
8.2 Safety Variables........................................................................................................... .............................................................. 18
8.3 Other Variables ............................................................................................................................... ............................................ 19
Definitions.................................................................................................................... .................................................................... 19
9.1 Baseline and Change  from Baseline.......................................................................................... ........................................ 19
9.2 Baseline-adjusted FEV 1 AUC 0-24h ............................................................................................................................... .......... 19
9.3 Treatment, Washout and Follow-up........................................................................................... ...................................... 20
9.4 Double-blind Period vs . Open-label Period .................................................................................. ................................. 20
9.5 Treatment Emergent Ad verse Event (TEAE).................................................................................... ............................ 21
9.6 Serious Adverse Event (SAE)................................................................................................ ............................................... 21
9.7 Spirometry (Part 1 Only)................................................................................................... .................................................... 21
9.8 Spirometry (Part 1 and 2).................................................................................................. ................................................... 23
9.9 COPD Exacerbations (P art 1 and Part 2) ..................................................................................... ................................... 23
9.10 COPD Symptom Scores (Pa rt 1 and Part 2)................................................................................... .............................. 23
9.11 Methods for Handling Dro pouts and Missing Data............................................................................ ...................... 24
Analysis Population ............................................................................................................ ....................................................... 25
10.1 Intention-to-Treat ........................................................................................................ ......................................................... 25
10.2 Per Protocol.............................................................................................................. ................................................................ 25
10.3 Safety.................................................................................................................... ....................................................................... 26
10.4 Part 2 of the Study....................................................................................................... .......................................................... 26
10.5 All Subjects .............................................................................................................. ................................................................. 26
10.6 All Randomized Subjects ................................................................................................... ................................................. 26
Interim Analysis ............................................................................................................... ........................................................... 26
11.1 Objective of the Interim Analysis ......................................................................................... ........................................... 26
11.2 Endpoint for the Interim Analysis ......................................................................................... ......................................... 26
11.3 Interim Analysis Population............................................................................................... ............................................... 26
11.4 Sample Size Re-calculation  for the Interim Analysis ....................................................................... ....................... 27
11.4.1 Intra-patient CV Estimation............................................................................................. ......................................... 27
11.4.2 Sample Size Re-calculation.............................................................................................. .......................................... 28
11.5 Results of the In terim Analysis ........................................................................................... ............................................. 29
Data Review .................................................................................................................... .............................................................. 29
12.1 Data Handling and Transfer ................................................................................................ .............................................. 29
12.2 Data Screening ............................................................................................................ ............................................................ 30
Statistical Methods............................................................................................................ ......................................................... 30
Statistical Analysis Plan
Version Date:Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB-DPI-301
Page 3 of 49
Strictly Confidential.  © 2004-2015, .  All rights reserved.13.1 Subject Disposition....................................................................................................... ......................................................... 30
13.2 Protocol De viations....................................................................................................... ........................................................ 30
13.3 Treatments ................................................................................................................ ............................................................... 31
13.3.1 Extent of Study Drug Exposure........................................................................................... ..................................... 31
13.3.2 Prior and Concomit ant Medications....................................................................................... ............................... 31
13.4 Demographic and Baseli ne Characteristics .................................................................................. .............................. 32
13.5 Medical History........................................................................................................... ............................................................ 32
13.6 Efficacy Analyses......................................................................................................... ........................................................... 32
13.6.1 Primary Variable........................................................................................................ .................................................... 32
13.6.2 Statistical Analysis for  the Primary Variable ........................................................................... .......................... 32
13.6.3 Subgroup Analyses ....................................................................................................... ................................................ 35
13.6.4 Multiplicity............................................................................................................ ........................................................... 35
13.6.5 Pooling of Sites ........................................................................................................ ....................................................... 35
13.7 Safety Analyses ............................................................................................................ ........................................................... 35
13.7.1 Adverse Events.......................................................................................................... ..................................................... 36
13.7.2 Laboratory Data......................................................................................................... .................................................... 37
13.7.3 Vital Signs ............................................................................................................. ............................................................ 37
13.7.4 Physical Ex aminations ................................................................................................... ............................................. 37
13.7.5 HEENT, Chest Examination, an d Electrocardiograms (ECG) .................................................................. .... 37
13.7.6 COPD Exacer bations...................................................................................................... ............................................... 38
13.7.7 Safety Spirometry....................................................................................................... ................................................... 38
13.7.8 EXACT/ER-S Scores....................................................................................................... ............................................... 38
13.7.9 Albuterol/Salb utamol Usage .............................................................................................. ...................................... 38
13.7.10 Urine/Serum Pregnancy Test............................................................................................. ................................... 38
13.7.11 Urine Drug Screen ...................................................................................................... ................................................ 38
13.7.12 Inhaler Robustness (Pa rt 1 and Part 2)................................................................................. ............................ 39
Validation..................................................................................................................... .................................................................. 39
References ..................................................................................................................... ................................................................ 39
Appendix 1 Glossary of Abbreviations........................................................................................... .............................................. 40
Appendix 2: EXACT DAILY DIARY .................................................................................................. ............................................... 42
Appendix 3: Results from the Interim Analysis .................................................................................. ..................................... 45
Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 4of 49
Strictly Confidential.  © 2004 -2015 , .  All rights reserved.
Purpose
The statistical analy sis plan (SAP) describes the statistical methods to be used during the reporting and 
analyses of data collected under Lupin Inc. Protocol TB -DPI-301.
Scope
This plan is a living document that will be created during the trial start-up.  Statistical Analy sis Plan
(SAP) 1 will be drafted within three months of the final case report form (CRF ), and maintained 
throughout the lifecy cle of the trial.  The Statistical Anal ysis Plan 2 will be finalized prior to database 
lock. SAP 1 and SAP 2 will require sign off from the Project Manager and the sponsor.  
The Statistical Analy sis Plan outlines the following:
Study  objectives
Study  desi gn
Variables anal yzed and analy sis sets
Applicable study  definitions
Interim Anal ysis
Statistical methods regarding subject disposition, 
important protocol deviations, study  drug 
exposure, prior and concomitant medications, demographic and baseline charact eristics, medical 
history , efficacy  analy sis, adverse events handling, and other safet y data examinations 
The Table, Listing and Figure Shells will be provided in a separate document. 
Introduction
This SAP describes the statistical methods to be used during the reporting and analy ses of data collected 
under Lupin Inc. Protocol TB -DPI-301. 
This SAP should be read in conjunction with the study  protocol and CRF. This version of the plan has 
been developed using the protocol Amendment version 1 dated 11May 2017 and CRF dated 14Mar 2017. 
Any further changes to the protocol or CRF may  necessitate u pdates to the SAP.
The SAP is to be developed in two stages. The purpose is to “finalize” a SAP so that PRA can start 
programming earlier in the process. Versions of the SAP up to initial sponsor approval will be known as 
SAP1. Changes following approval of SAP1 will be tracked in the SAP Change Log and a final version 
of the SAP, known as SAP2, will be issued for sponsor approval prior to database lock.
Study  Objectives
Primary  Objective 
The primary  objective of this study  is to show clinical Bioequivalence ( BE)in the efficacy  of the Lupin 
Tiotropium Bromide Inhalation Powder, 18 mcg administered as a single dose versus SPI RIVA 

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 5of 49
Strictly Confidential.  © 2004 -2015 , .  All rights reserved.HANDIHALER, 18 mcg based on the baseline -adjusted forced expiratory volume in the first second 
(FEV 1) area under the curve from time zero to 24 hours postdose (AUC 0
-24h) on day  1. 
Secondary  Objectives
The secondary  objectives of this study  are to evaluate the safet y and tolerability  of the Lupin Tiotropium 
Bromide Inhalation Powder and SPI RIVA HANDIHAL ER following single doses of 18 mcg in patients 
40 years of age and older with COPD. 
Other Objectives 
For a subset of the Lupin tiotropium DPIs (LUPINHALER™) used during the open -label extension 
(Part 2) the following objectives will be assessed: 
rugged ness of the LUP INHALER during 72 days of in -patient use 
in vitro performance post 72 day s of in -patient use 
Study  Design
This is a Phase 3 Randomized, Double -Blind, Double -Dummy , Placebo -Controlled, Crossover, 
Multicenter Clinical Study to Assess the Eff icacy  and Safety of Once Daily Administration of L upin 
Tiotropium Bromide Inhalation Powder Compared to SPI RIVA®HANDIHALER®and Placebo in 
Patients with COPD including a 12 -Week Open
-Label Extension to assess I nhaler Robustness. The 
study  is planned to be conducted at approximately 40 investigational centers in the United States of 
America (USA). Additional centers in the USA may  be added as needed. 
This clinical study  includes two parts. The duration of patient participation for Part 1 is approximately 
14 weeks and for patients participating in both Part 1 and Part 2, the duration of patient participation is 
approximately  26 weeks.
Part 1 (14 weeks)
Part 1 is a randomized, double -blind, double -dummy , placebo -controlled, 3 -period, single -dose 
crossover stud y that will evaluate the clinical BE of single -dose treatment of L upin Tiotropium Bromide 
Inhalation Powder, 18 mcg and SP IRIVA HANDIHALER, 18 mcg in patients 40 y ears of age and older 
with established COPD. 
Part 1 of the study consists of a screening period up to 30 day s, followed by a single -blind placebo run
-
in period of 14 (+2) day s and 3 single -dose, double -blind treatment periods (visits 2 -4) each separated 
by a 21 -day (+3 day s) washout period. Each double -blind treatment period begins with administration of 
the study  medication at the investigational center, followed b y lung function assessments collected over 
a 24-hour period. For patients ending participation in the study  after completing Part 1 and not enrolling 
into the open- label extension (Part 2), a follow -up visit via phone contact will be conducted 7 day s 
(±3days) after the completion of treatment period 3 (visit 4). 

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 6of 49
Strictly Confidential.  © 2004 -2015 , .  All rights reserved.Screening period: up to 30 day s
The screening period allows for adequate washout of the COPD therapies including long-acting 
anti-muscarinic agent ( LAMA ), long -acting beta agonist ( LABA ), or inhaled corticosteroid ( ICS)/LABA 
therap y, along with other prohibited medications per protocol .If a patient is washing out of ICS 
(monotherap y) or ICS/LABA combination therapy  as stated above, an additional 3 day window is 
permitted to complete the assessments for the screening visit (visit 1).
If the patients were formerly  taking LAMA, LABA, or ICS/L ABA therap y, the medications will need to 
be discontinued and may  be replaced at the discretion of the Investigator with the short -acting anti -
muscarinic agent (SAMA) medication, ipratropium bromide, for use during the course of the study . 
Patients who have not taken LAMA, LABA or ICS/LABA combination products within the time period 
specified above, or who are not on medications that are restricted according to the protocol criteria, and 
who have met the se lection criteria (e .g., reversibility  and baseline safet y measures) at the screening visit 
(visit 1) will begin the 14 (+2) day single -blind placebo run- in period.
All patients enrolled in the screening/run -in periods will be supplied with the following: 
eDiary /electronic flow meter to measure lung function for monitoring disease stability  during the 
screening and run- in periods
short -acting bronchodilator (SABA), ie, albuterol/salbutamol metered dose inhaler 
(MDI) 90mcg ex -actuator or equivalent, for us e during the course of the study
Single -blind placebo run- in period: 14 (+2) day s 
Patients enrolled in the run- in period will also be supplied with a placebo Lupin Tiotropium Bromide 
Inhalation Powder (placebo LUPINHALER) for once dail y administration (2 inhalations from one 
capsule) in the morning throughout the single -blind run -in period. 
Patients will be required to measure FEV 1prior to dosing in the morning at approximately  the same time 
each day . The FEV 1results and usage of stud y medication/albu terol/salbutamol MDI  will be monitored 
and recorded in the eDiary . Patients will also complete the Exacerbations of Chronic Pulmonary  Disease 
Tool (EXACT®) Patient Repo rted Outcome (PRO) within the eDiary , once daily , each evening before 
bedtime during the screening and run -in periods. 
Three single -dose, double -blind treatment periods (visits 2 -4) each separated by  a 21 -day (+3 day s) 
washout period 
Patients will present at the investigational center for visit 2 on day  0 between 0600 and 1000 having 
withheld the prohibited/restricted medications for the prescribed protocol -defined period and without 
conducting lung function measurements on the electronic flow meter (home device). Patients will record 
albuterol/salbutamol M DI usage in their diaries on the mornings prior to this visit. Patients meeting all 
of the randomization criteria will be randomly assigned to 1 of the following 6 treatment sequences in a 
double -dummy  manner using a Williams design Latin Square as describ ed in Table 1: 

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 7of 49
Strictly Confidential.  © 2004 -2015 , .  All rights reserved.Table 1  Randomization Design
Treatment 
sequence Treatment period 
1 Treatment period 
2 Treatment period 
3 
A (TRP) Lupin Tiotropium 
Bromide 
Inhalation Powder 
18 mcg SPIRIVA 
HANDIHALER 
18 mcg Placebo 
B (RPT) SPIRIVA 
HANDIHALER 
18 mcg Placebo Lupin Tiotropium 
Bromide 
Inhalation Powder 
18 mcg 
C (PTR) Placebo Lupin Tiotropium 
Bromide 
Inhalation Powder 
18 mcg SPIRIVA 
HANDIHALER 
18 mcg 
D (PRT) Placebo SPIRIVA 
HANDIHALER 
18 mcg Lupin Tiotropium 
Bromide 
Inhalation Powder 
18 mcg 
E (TPR) Lupin Tiotropium 
Bromide 
Inhalation 
Powder18 mcg Placebo SPIRIVA 
HANDIHALER 
18 mcg 
F (RTP) SPIRIVA 
HANDIHALER 
18 mcg Lupin Tiotropium 
Bromide 
Inhalation Powder 
18 mcg Placebo 
In order to maintain the patient blind, a specified member of the investigational center (i .e., unblinded 
administrator) will load and dispense the study medication to the patient and instruct the p atients to take 
2 full inhalations from each of 2 inhalers. The unblinded administrator will also apply an opaque 
covering to the chamber windows prior to patient administration to obstruct capsule identification in 
each inhaler. 
Patients will undertake 2 baseline FEV 1 measurements at 0 hours ( -30 and -15 minutes before stud y 
medication administration) followed b y serial FEV 1measurements at 5 and 30 minutes postdose , and at 
1, 2, 4, 6, 8, 10, 12, 23, and 24 hours postdose . The 23 and 24 hour FEV 1measurements will be taken on 
the 2ndday of the visit (day  1) in the morning at the investigational center. Prior to and for the duration 
of the FEV1 measurements at the investigational center visits (day  0 and day  1), patients should refrain 
from using a lbuterol/salbutamol MDI  and other prohibited medication; patients should not smoke for at 
least 1 hour prior to lung function assessments during the visit; and patients should adhere to the dietary 
restrictions as per protocol. 

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 8of 49
Strictly Confidential.  © 2004 -2015 ,   All rights reserved.After completion of all assessments at visit 2, the patients will enter a 21 -day (+3 day s) washout phase 
where the patients may  continue to use albuterol/salbutamol MDI  and other medications permitted per 
protocol (eg, SAMA). Patients will continue to measure lung function for monitoring disease stability 
during the double -blind treatment period. On day s of non -investigational center visits, patients will be 
required to measure FEV 1once daily  prior to dosing in the morning at approximately  the same time each 
day. The FEV 1will be r ecorded in the eDiary /electronic flow meter. Patients will also complete the 
EXACT once daily , each even ing before bedtime within the eDiary . On days of investigational center 
visits, patients will perform the FEV 1measurements and administer the study med ication at the 
investigational center, and the EXACT will be collected at home in the evening before bedtime. Usage 
of albuterol/salbutamol MDI will also be recorded in the eDiary . 
Prior to visit 3 (day s 21 and 22) and visit 4 (day s 42 and 43) patients s hould observe the same smoking, 
dietary  and medication restrictions as visit 2. Patients will record albuterol/salbutamol MDI  usage in 
their diaries on the mornings prior to these visits; however, no FEV 1measurements will be performed in 
the morning using the electronic flow meter (home device). Patients should present at the investigational 
center so that the start of lung function testing will be within ±1 hour from the lung function testing at 
visit 1. Patients will then undertake 2 baseline FEV 1measur ements at 0 hours ( -30 and -15 minutes 
before stud y medication administration), followed by serial FEV1 measurements at 5 and 30 minutes 
post-dose, and at 1, 2, 4, 6, 8, 10, 12, 23, and 24 hours post-dose. After completion of all assessments at 
visit 3 (da ys 21 and 22), the patient will enter a 21 -day (+3 day s) washout phase where the patient may  
continue to use albuterol/salbutamol MDI  and other medications permitted per protocol (eg, SAMA). 
Follow -up period: 7 day s (±3 day s)
Patients who successfully com plete the 3 single -dose treatments in Part 1 and who are not enrolled into 
the open- label extension (Part 2) will be contacted via phone 7 day s (±3 day s) after the visit for a final 
safet y check and then formally discharged from the study.
Part 2 (12 weeks)
Part 2 is a 12 -week open- label extension of Part 1, which will enroll a subset of patients (approximately  
120 patients) 
at select investigational centers who successfull y completed Part 1 of the stud yand 
continue to meet the continuation crite ria, to assess robustness of the LUPINHALER over 72 day s of 
treatment. 
The open -label extension (Part 2) will consist of 7 visits (visit 5 through visit 10, and follow -up), and 
will begin on the last day of visit 4 (Part 1). Visits 6 and 8 will be conduc ted via telephone contact. The 
final safet y follow -up for those patients participating in Part 2 will be conducted via telephone 7 days 
(±3 day s) after the last active treatment of the open -label extension (ie, visit 10). 
Patients participating in the open -label extension will begin study  activities on the same day  as the final 
visit in the double -blind treatment period (visit 4), which will be considered the first day of the open -
label extension (visit 5). Patients will be issued a 90 -day supply  of the T iotropium Bromide Inhalation 

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 9of 49
Strictly Confidential.  © 2004 -2015 , .  All rights reserved.Powder, 18 mcg for once -daily  administration (to be taken at home each morning) during a 72 -day 
treatment phase. Treatment with the Lupin Tiotropium Bromide Inhalation Powder will begin on visit 5 
after all FEV1 assessments and study  activities were completed for Part 1. Patients will be permitted to 
resume other non
-study  medications and albuterol/salbutamol MDI  as permitted per protocol. LAMA 
medications (mono and combination therapies), other than the stud y medication, are pr ohibited in Part 2 
of the study . Patients will assess functionality  of the LUPINHALER dail y and record this data in the 
eDiary .
Patients will measure lung function to monitor disease stability via the eDiary /electronic flow meter 
during the open -label ext ension. Patients will be required to measure FEV 1twice dail y: upon awakening 
in the morning immediately  prior to dosing with the study  medication and at 2 (+2) hours after study  
medication administration. The FEV 1results and albuterol/salbutamol MDI/stud y medication usage will 
be monitored and recorded in the eDiary /electronic flow meter. Patients will also complete the EXACT 
once dail y, each evening before bedtime within the eDiary . 
At visit 6 and visit 8, patients will be contacted via telephone b y investigational center personnel to 
monitor AEs and an y issues regarding the inhaler function. The patients will return to the investigational 
center on visit 7 and visit 9 for an overall assessment of safet y and tolerability , to verify  inhaler 
technique, an d to assess any  inhaler issues/malfunctions. On visit 10, patients will return for a final 
treatment visit, in which vital signs will be assessed, inhaler issues/malfunctions assessed, and the 
eDiary /electronic flow meter, albuterol/salbutamol MDI , and stu dy medication collected and stored 
appropriatel y. The patient should be contacted via phone 7 ±3 days after the final treatment visit (visit 
10) for a final safety  check and to be formally  discharged from the study . 
Safety  will be monitored throughout Part 1 and Part 2 of the study  by vital signs measurements, 
albuterol/salbutamol MDI and concomitant medication usage, ph ysical examinations, head, ears, eyes, 
nose, throat (HEENT)/chest examinations, spirometry ( FEV 1) measurements, electrocardiograph y 
(ECG s), ER -S: COPD scores (derived from the EXACT), COPD exacerbations, and AEs. During the 
screening and run- in periods, safet y will be assessed via FEV 1measurements, ER -S: COPD scores, and 
monitoring of AEs and COPD exacerbations.
The schedule of events 
for this study  is provided in Table 
2Schedule of Events.

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 10of 49
Strictly Confid ential.  © 2004 -2015 , .  All rights reserved.Table 2Schedule of Events
Screening 
periodSingle -
blind 
run-in 
periodPart 1
Double -blind treatment periodPart 2
Open -label extension
Study visit Visit 1 NA TP1
(Visit 2)TP2
(Visit 3)TP3
(Visit 4)F/U1Visit 
5Visit 
6Visit 
7Visit 
8Visit 
9Visit 
10F/U2ET3
Study days4-44 to -14514-16
day 
period 
before 
day 00 1 21
(+3)22 42
(+3)43 50
(±3)43657
(±2)71
(±2)85
(±2)99
(±2)115
(+3)122
(±3)NA
Clinic visit7X X X X X X X Tele-
phone 
onlyX Tele-
phone 
onlyX Tele-
phone 
onlyX X Tele-
phone 
onlyX
Informed consent X
Assign patient via IRT X
Assess inclusion/ 
exclusion criteriaX
Demography X
Physical examination X8X X X
Height and weight X
HEENT and chest 
examinationX X X X X
Medical history 
including prior 
concomitant 
medicationsX
12-lead ECG X X X X X X X
Clinical laboratory 
tests (hematology, 
biochemistry, and 
urinalysis)X
Serum pregnancy test 
(female patients ofX X9X9X

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 11of 49
Strictly Confid ential.  © 2004 -2015 , .  All rights reserved.Screening 
periodSingle -
blind 
run-in 
periodPart 1
Double -blind treatment periodPart 2
Open -label extension
Study visit Visit 1 NA TP1
(Visit 2)TP2
(Visit 3)TP3
(Visit 4)F/U1Visit 
5Visit 
6Visit 
7Visit 
8Visit 
9Visit 
10F/U2ET3
Study days4-44 to -14514-16
day 
period 
before 
day 00 1 21
(+3)22 42
(+3)43 50
(±3)43657
(±2)71
(±2)85
(±2)99
(±2)115
(+3)122
(±3)NA
Clinic visit7X X X X X X X Tele-
phone 
onlyX Tele-
phone 
onlyX Tele-
phone 
onlyX X Tele-
phone 
onlyX
childbearing potential 
only)
Urine pregnancy test 
(female patients of 
childbearing potential 
only)X
Urine drug screen X
Vital signs 
measurements10XX11 XX11 XX11 X X X X X
Demonstrate study 
medication inhalation 
techniqueX X X X X X X
Demonstrate 
albuterol/salbutamol 
MDI inhalation 
techniqueX X X X X X X
Dispense single -blind 
run-in medicationX12
Assess inspiratory flow 
rate via In -Check 
DIAL deviceX X X X
Ipratropium 
reversibility13X

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 12of 49
Strictly Confid ential.  © 2004 -2015 , .  All rights reserved.Screening 
periodSingle -
blind 
run-in 
periodPart 1
Double -blind treatment periodPart 2
Open -label extension
Study visit Visit 1 NA TP1
(Visit 2)TP2
(Visit 3)TP3
(Visit 4)F/U1Visit 
5Visit 
6Visit 
7Visit 
8Visit 
9Visit 
10F/U2ET3
Study days4-44 to -14514-16
day 
period 
before 
day 00 1 21
(+3)22 42
(+3)43 50
(±3)43657
(±2)71
(±2)85
(±2)99
(±2)115
(+3)122
(±3)NA
Clinic visit7X X X X X X X Tele-
phone 
onlyX Tele-
phone 
onlyX Tele-
phone 
onlyX X Tele-
phone 
onlyX
Study qualifying FEV 1 X
Determine FEV 1
baseline/stability limitsX14X15
Administer
single -blind run -in 
medicationX
Collect single-blind 
run-in medicationX X
Review randomization 
criteriaX
Randomization via 
IRTX
Review continuation 
criteriaX X X X X X X
Administer study 
medication at clinicX X X X
Enroll in open -label 
extension via IRT16X
Predose and serial 
FEV 1measurements17X X X X X X
Dispense eDiary / 
electronic flow meterX18 X
Review eDiary / 
electronic flow meter 
instructionsX X X X X

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 13of 49
Strictly Confid ential.  © 2004 -2015 , .  All rights reserved.Screening 
periodSingle -
blind 
run-in 
periodPart 1
Double -blind treatment periodPart 2
Open -label extension
Study visit Visit 1 NA TP1
(Visit 2)TP2
(Visit 3)TP3
(Visit 4)F/U1Visit 
5Visit 
6Visit 
7Visit 
8Visit 
9Visit 
10F/U2ET3
Study days4-44 to -14514-16
day 
period 
before 
day 00 1 21
(+3)22 42
(+3)43 50
(±3)43657
(±2)71
(±2)85
(±2)99
(±2)115
(+3)122
(±3)NA
Clinic visit7X X X X X X X Tele-
phone 
onlyX Tele-
phone 
onlyX Tele-
phone 
onlyX X Tele-
phone 
onlyX
Dispense 
albuterol/salbutamol 
MDI, as applicableX19 X X X X X X X
Dispense/collect 
placebo trainerX X X X
Dispense study 
medication20X X X X
Assess eDiary data X X X X X X X X X X X
Collect eDiary /
electronic flow meter, as 
applicableX X X X X
Check for issues with 
study inhalersX X X X X X X X X XX21
Collect COPD 
exacerbation dataX X X X X X X X X X X X X X X X X
Record AEs X X X X X X X X X X X X X X X X X
Record concomitant 
medication/therapiesX X X X X X X X X X X X X X X X X
Collect study 
medicationX X X X X
Collect 
albuterol/salbutamol 
MDI, as applicableX X X X X X X X X
Schedule next visit X X X X X X X X X X

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 14of 49
Strictly Confid ential.  © 2004 -2015 , .  All rights reserved.Screening 
periodSingle -
blind 
run-in 
periodPart 1
Double -blind treatment periodPart 2
Open -label extension
Study visit Visit 1 NA TP1
(Visit 2)TP2
(Visit 3)TP3
(Visit 4)F/U1Visit 
5Visit 
6Visit 
7Visit 
8Visit 
9Visit 
10F/U2ET3
Study days4-44 to -14514-16
day 
period 
before 
day 00 1 21
(+3)22 42
(+3)43 50
(±3)43657
(±2)71
(±2)85
(±2)99
(±2)115
(+3)122
(±3)NA
Clinic visit7X X X X X X X Tele-
phone 
onlyX Tele-
phone 
onlyX Tele-
phone 
onlyX X Tele-
phone 
onlyX
Discuss COPD 
treatment optionsX X X X X X
Discharge patient via 
IRTX X X
Home -based FEV 1 
measurementsRecord morning pre-dose in eDiary /electronic flow meter22Record morning pre-dose and 2 hours post-dose
in eDiary /electronic flow meter
Assess EXACT 
symptom scoresRecord once daily in t he evening before bedtime via eDiary Record once daily in evening before bedtime via 
eDiary
Albuterol/salbutamol 
MDI medication useRecord daily in eDiary Record daily in eDiary
1)For patients participating in Part 1 only, a follow -up visit will occur via phone contact by investigational center personnel 7 days (±3 days) after completing 
visit 4.
2)This follow -up visit will only be required for patients participating in Part 2 of the study, and will occur via phone contact by investi gational center personnel 7 
±3days after th e final treatment visit (visit 10).
3)Regardless if patient is participating in Part 1 or Part 2, the assessments listed for ET w ill be performed for any patient who is withdrawn prem aturely from the
study.
4)As there is only the potential to extend visit intervals with perm itted visit windows, the terminology of study days will not necessarily represent theexact day 
of the visit.
5)The screening visit (visit 1) may take place over several days beginning on day -44 to -14 dependent on the patient’s washout. If a patient is washing out of 
ICS (monotherapy) or ICS/LABA combination therapy, an additional 3 days is permitted to complete the assessments for the screening visit (visit 1). All 
results , with the exception of the clinical laboratory assessments, must be available and evaluated prior to commencing the run-inperiod.   The clinical 
laboratory results must be available and evaluated prior to random izatio n.  The procedures for the screening visit (visit 1), with the exception of signing of the 
ICF, performing a pre-washout physical examination, and dispensing/completing the ediary, cannot occur until appropriate medication washouts have b een 

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 15of 49
Strictly Confid ential.  © 2004 -2015 , .  All rights reserved.completed in accor dance with the protocol.  Once the w ashout requirements have been met, the screening visit (visit 1) should immediately prece de the start of 
the run-in period.  If a patient does not require washout, and the patient passes all entry  criteria at the screeni ng visit (visit 1), the patient will be eligible to 
enter the run-in period on the same day as the screening visit (visit 1).  The patient must successfully complete the visit 1 procedures/as sessments prior to 
entering the run -in period.
6)After completion o f visit 4 (days 42 and 43), patients will either be discharged from the study after completing all dou ble-blind study assessments at visit 4 or a 
subset of patients (approximately 120 patients) will be eligible for enrollment into a 12-week open -label extension, which will begin on the same day as the 
final visit in the double blind treatment period.
7)All visits for Part 1 should be scheduled in the mornings betw een 0600 and 1000 and spirometry testing should begin at ±1 hour of the start of visit 1 testing
time.
8)If washout of baseline therapy is needed, then 2 physical examinations are required: one before a patient commences the washo ut period and one after the 
washout period ends, prior to enrolling into the run -inperiod.
9)The visit 4 end of study serum pregnancy test will be performed for women of childbearing potential who are only participating in Part 1 of the study. For 
women ofchildbearing potential who areparticipating inboth Part1andPart2,theendofstudy serum pregnancy testwillbeperformed atvisit 10.
10)Vital signs measurements include blood pressure, heart rate, respiration rate, andtemperature.
11)Vital signs willbecollected within 60minutes ofmeasuring thepredose FEV 1ondays 0, 21, and42.
12)Single blind run-in must be dispensed 14 to 16 days prior to randomization. Patients will administer the single -blind placebo LUPINHALER one daily  in the 
morning for 14 (+2) days after completing the FEV 1measurements.
13)Patient has demonstrated ≥15% reversibility of FEV 1within 30 or 60 minutes following 68 mcg of ipratropium bromide inhalation (pMDI). If required, spacers 
are permitted for use during reversibility testing for ipratropium brom ide administration . Patients who do not demonstrate a positive improvement of at least 
15% in FEV 1measured at 30 or 60 minutes (±5 minutes) post inhalation will not be eligible to participate in the study. However, based onInvestigator 
judgment, patients will be allow ed to retest once no sooner than 24 hours and no later than 2 weeks after initia l failure to meet the reversibility criteria. 
Reversibility values of 14.50 -14.99 w ill be rounded to 15.
14)A stability limit will be established at the screening visit (visit 1) to determine alert criteria for worsening COPD during the screening and run-in periods, and
willbecalculated byselecting thebestpre-bronchodilator qualifying FEV 1measurement atthescreening visit using theonsite spirom eterx80%.
15)Two stability limits (at home and investigational center) will be re-established at the random ization visit (visit 2) for use during the double -blind and open -
label treatment periods. The at home limit will be calculated by taking the mean of the best predoseFEV 1measurements on the last 3 days before 
random ization on the electronic flow meter (hom e device) x 80%, and the investigational center limit will be the mean FEV 1of the predose pre-bronchodilator
qualifying FEV 1measurements (-30and-15minutes) using theonsite spirom eter×80%.
16)A subset of patients (approximately 120 patients) at select investigational centers who successfully completed Part 1 will beeligible for enrollment into the 
open -label extension (Part 2).
17)Pre-dose FEV 1 will be measured at 30 and 15 minutes before administration of study medication.  Serial FEV 1spirom etry measured at 0 hours (within 30 and 
15 m inutes prior to study medication administration [equivalent to the pre-dose FEV 1]), and at 5 and 30 m inutes post-dose, and at 1, 2, 4, 6, 8, 10,12, 23, and 
24 hours post-dose. The following 
windows are permitted: +5 minutes for predose measurements ( -30 and -5 minutes) and 5 m inute postdose measurement ; ±5 
minutes for 0.5 -6 hours, and ±15 minutes for 8 -24 hours.
18)Diary collection begins at the time of signing the ICF until the conclusion of the run-in period, and then continues throughout Part 1 and Part 2, per the 

Statistical Analysis Plan
Version Date: Final 08Feb 2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 16of 49
Strictly Confid ential.  © 2004 -2015 , .  All rights reserved.random ization scheme.
19)Dispensation of the albuterol/salbutamol MDI is not required during the screeni ng period if the patient is taking this medication as part of their current COPD 
therapy. Once the patient is enrolled in the run-in period, dispensation/administration of the study albuterol/salbutamol MDI is required and the patient will 
discontinue the use of their own albuterol/salbutamol MDI.
20)Administration ofstudy medication attheinvestigational center willoccur inthepresence oftheunblinded and blinded staff member s.
21)For patients participating in Part 2.
22)Hom e based FEV 1measurements will not be performed on the mornings of visit 2 (both day 0 and day  1), visit 3 (both day 21 and day  22), and visit 4 
(both day 42 and day 43).

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 17of 49
Strictly Confidential.  © 2004 -2015 , .  All rights reserved.7.1Sample Size Considerations
The sample size estimation was determined based on demonstrating equivalence between the 
Test (T) product (Lupin Tiotropium Bromide Inhalation Powder) and the Reference (R) 
product (SPI RIVA HANDIHALER) for the primary  endpoint change from baseline in FEV 1
AUC 0-24 on the treatment day, and to demonstrate that both the Test (T) and Reference (R) 
products are superior to the placebo. Bioequivale nce (BE) will be demonstrated if the 90% 
confidence interval (CI) on the T to R ratio for the endpoint is contained within the interval 
(0.80, 1.25). Superiorit y will be demonstrated b y showing that each active treatment’s 
response for the endpoint is grea ter than, and statistically  different from (p<0.05, two -sided), 
that of the placebo (P). For the equivalence evaluation, the results in the PP anal ysis set will 
be considered definitive and for the superiority evaluations, those in the I ntent -to-
Treat (ITT ) 
population will be considered definitive. 
A review of the literature did not y ield any  estimates of within -patient variability  of baseline -
adjusted FEV 1AUC 0
-24 from a crossover stud y using a similar patient population with similar 
objectives. From a review of studies on clinicaltrials.gov, there were a number of estimates 
available of between- patient variability  for baseline -adjusted FEV 1AUC 0-24. From the 
12studies reviewed, the mean coefficient of variation (CV) for the variable was 121%. 
Within -patient variability  is generall y much less than between -patient variability . As a 
starting point for the sample size estimation it was assumed that the within
-patient variability  
would be about 50% of the between -patient variability , or a CV of 60%. 
The goal of the stud y is to complete 180 patients per protocol. With a sample size in each of 
the 6 sequence groups of 30, for a total sample size of 180, a crossover desig n will have 90% 
power to reject both the null hy pothesis that the ratio of the test mean to the standard mean is 
below 0.80 and the null hypothesis that the ratio of test mean to the standard mean is above 
1.25 (ie, that the test and standard are not equiv alent), in favor of the alternative hy pothesis 
that the means of the 2 treatments are equivalent, assuming that the expected ratio of means 
is 1.00, the between -patient CVis 1.21, the intra -patient 
CV is 0.60. I n order to allow for a 
potential 30% premature withdrawal rate or loss from the PP population due to protocol 
deviations, 240 patients will be randomized in total, 40 to each of the 6 treatme nt sequences. 
As no estimates of within -patient variability  were available in the public domain, a blinded 
interim analy sis will be conducted in order to assess the within -patient variability . The 
blinded interim analysis will be done to ascertain if an increase in sample size is necessary  
maintain 90% power to complete the study  with a 90% CI  for the relative bioavailability  of 
the Test (T) to the Reference (R) product inside of the pre -specified interval 0.80 -1.25. The 
blinded interim analy sis will be discussed in Section 11.0. 

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 18of 49
Strictly Confidential.  © 2004 -2015 , .  All rights reserved.7.2Randomization
Patients will be randomly assigned to the treatment sequences b y means of a computer 
generated randomization list after confirmation of all eligibility criteria. The randomization 
list and study  medication will be assigned via interactive response technolo gy (IRT). Y-
Prime I nc.will be responsible for generating t he randomization schedule .
The r andomization scheme utilized in TB -DPI-301 will be central. A total of 240 p
atients
will be randomized in a ratio of 1:1:1:1:1:1 to the 6treatment sequences based on a Williams 
design Latin square in the c ross-o ver design shown in Table 1. 
Additionally , on each study  day, as this is a double -dummy  study , the order of administration 
of the L UPINHALER and HANDIHALER will be assigned based on even/odd calendar day s.
On odd calendar day s (eg, 1, 3, 5, 29, 31), the LUPINHALER will be dosed first.  On even 
calendar day s (eg, 2, 4, 6, 28, 30), the HANDIHALER will be dosed first . 
A subset of approximately 120 patients (at select investigational centers) will be enrolled into 
the open- label phase of the study  (Part 2). These patients will not be randomized and all 
patients in Part 2 will receive Lupin Tiotropium Bromide Inhalation Powder.
Study  Variables 
8.1Primary Efficacy Variable
The primary  variable is the baseline -adjusted FEV 1AUC 0-24h on the single -dose treatment 
days. Baseline is defined as the average of the FEV 1values recorded at approximately  
30minutes and 15 minutes before dosing with study medication. 
8.2Safety Variables
Safety  will be assessed throughout Part 1 and Part 2 of the study  by monitoring the following: 
adverse events (AEs) 
SABA (albuterol/salbutamol MDI ) and concomitant medication use 
vital signs measurements 
physical examinations 
head, ears, ey es, nose, a nd throat (HEENT) and chest examinations 
COPD exacerbations 
12
-lead electrocardiograms (ECGs)
Laborator y(screening only )
ER-S: COPD Scores
Safety  Spirometry

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 19of 49
Strictly Confidential.  © 2004 -2015 , .  All rights reserved.8.3Other Variables 
For a subset of the LUPI NHALERs used during the open -label extension (Part 2), the 
following endpoints will be assessed: 
ruggedness of the LUP INHALER during 72 days of in -patient use: 
-percent (%) of overall inhalers with reported problems or malfunctions ; 
comprised of misuse episodes (eg, impact and moisture) and issues identified (eg, 
mechanical 
problems and COPD worsening/seems ineffective) during 72 days of 
in-patient use 
in vitro performance of 100 inhalers post 72 day s of in -patient use 
The data re sulting from the in vitro evaluation of the pharmaceutical performance will 
be presented in a separate report.
Definitions
9.1Baseline and Change from Baseline
Baseline is defined as the last observation prior to dosing. Generall y, baseline in Part 2 of the 
study  will be the same as baseline in Part 1 of the study  unless otherwise specified. For the 
primary  variable ( FEV 1AUC 0-24h), baseline is defined as the average of the FEV 1values 
recorded at approximately  30 minutes and 15 minutes before do sing with study  medication.
Change from baseline = post-baseline value – baseli ne value. 
9.2Baseline- adjusted FEV 1 AUC 0 -24h 
The baseline -adjusted FEV 1AUC 0 -24h is defined as the baseline -adjusted area under the curve 
for forced expiratory  volume in 1 second from time zero to 24 hours postdose using the 
trapezoidal rule based on actual time of measurement. 
The baseline FEV 1will be the average of the 2 predose FEV1measurements (30 minutes and 
15 minutes pre -dose) at the clinic visit.  I f one of the predose FEV 1measurements is missing, 
or excluded due to poor quality  spirometry  effort , the other non -missing measurement will be 
used as baseline. If both predose FEV1measurements are missing or excluded , baseline will 
be treated as missing. 
Baseline -adjusted FEV 1will be calculated as postdose FEV 1after subtracting the baseline 
FEV 1value. 
The general area under the concentration -time effect curve (AUC) formula b y the trapezoid
al
rule is given below:
)
 (
2
1
i =1
1






i
 i
n
i
 i
t
t
c
 c
AUC (0– tn)

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 20of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.where tnis the maximum time, nis the number of time points, and ciis the change in FEV 1
from baseline at time ti. For AUC calculations t0will be the start time of dose administration
(t0=0),and c0will be 0. AUC calculations will utilize the actual time of spirometry 
measurements.
Note -the area under the curve that is the primary  variable is the area between the baseline 
value (straight red line and the curve). It is NOT measured from the x -axis.
9.3Treatment, Washout and Follow -up
For summary purpose s, treatment will be defined as days of dosing and day s immediate ly
after dosing , eg,day 0,1, 21(+3), 22, 42(+3) and 43; w ashout will be day s between 
treatments; follow -up is defined as 7 ±3day s after visit 4 for Part 1, for patients who did not 
enter into the open -label Part 2 extension . 
For Part 2, treatment is defined as first dosing date in Part 2 until the end of study  or early 
termination (
ET)for Part 2; follow -up is defined as 7 ±3day s after visit 10.
9.4Double -blind Period vs. Open -label Period
The d ouble -blind period is defined as Part1 of the study , from randomization tovisit 4 or 
early termination before visit 4 . For those who do not participate in Part 2 of the study  (open -
label), it also includes the follow -up period, which is 7±3day s after visit 4 .
Open -label period is defined as Part 2 of the stud y, from enrollment in Part 2 (open -label) to 
the end of Part 2 study  or ETfrom 
Part 2. I t also includes the follow- up period , which is
7±3day s after visit 10.

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 21of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.9.5Treatment Emergent Adverse Event (TEAE)
AEs will be summarized separately  for TEAEs and Non- TEAEs .
Non- TEAEs are AEs observed after signing ICF until the initiation of the dose of the first 
experimental treatment .
A TEAE is defined as an event with an onset date /time on or after the initiation of the dose of 
the first experimental treatment after randomization or an event that is present at the initiation 
of the study  medication and that subsequently  increases in severit y or frequency . AEs with a 
missing onset date and a stop date on or after 1st Dose Date or with a missing stop date, will 
be summarized as TEAEs .
9.6Serious Adverse Event (SAE)
An SAE is defined as an AE that results in an y of the following: 
death 
life-threatening
requires hospitalization or prolongs existing hospitalization 
results in persistent or significant disability or incapacity 
results in a congenital abnormality  or birth defect 
an important medical event which requires medical intervention to prevent any of the 
above outcomes 
9.7Spirometry (Part 1 Only)
FEV 1
The spirometry  endpoint data will be captured using standardized equipment supplied by a 
central spirometry  vendor - ERT.
All visits to the investigational center for Part 1 must be scheduled in the mornings between 
0600 and 1000 and spirometry testing should begin at ±1 hour of the start of visit 1 study  
qualify ing spirometry  testing time. Predose FEV 1measurements will be recorded at 0 hours 
(-30 and -15 minutes before administration of study  medication) at the investigational center 
at visits 1 through 4; serial FEV 1measurements will be recorded postdose at 5 and 30 
minutes, a nd at 1, 2, 4, 6, 8, 10, 12, 23, and 24 hours. 
The following windows are permitted: +5 minutes for predose measurements (
-30 
and -15minutes) and 5 minute postdose measurement ;±5 minutes for 0.5-6 hours, and ±15 
minutes for 8 -24 hours.
Reversibility  Testing 
For reversibility  testing, patients will receive 68 mcg of ipratropium bromide inhalation 
pMDI  as 4 actuations of 17 mcg/actuation (ex -mouthpiece); given at approximately  

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 22of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.30second intervals. If required, spacers are permitted for use during reversibility  testing for 
ipratropium bromide administration. All actuations are to be completed within 3 minutes of 
the 1st actuation. The ATS/ERS criteria will be followed for spirometry measures. Patients 
who do not demonstrate a positive imp rovement of at least 15% in FEV 1measured at 30 or 
60 minutes (±5 minutes) post inhalation will not be eligible to participate in the study (except 
as permitted per the retest specified below). Reversibility  values of 14.50 -14.99 will be 
rounded to 15. Ref er to the spirometry  manual for additional information related to 
reversibility  testing. Patients failing to meet the reversibility  requirement will be permitted to 
retest once, based on Investigator judgment (for only those patients who would normally 
achieve this level of reversibility ) no sooner than 24 hours and no later than 2 weeks after the 
initial failure.
FEV 1Stability  Limits 
FEV 1 stability  limits will be calculated for each patient at the screening visit (visit 1) using 
the onsite spirometer an d the randomization visit (visit 2), using both the home device and 
onsite spirometer. 
Screening Visit: 
The stability  limit established at the screening visit will be used to determine alert criteria for 
worsening COPD during the screening and run -in periods. The FEV 1stability  limit at the 
screening visit will be calculated as follows: 
Best pre -bronchodila tor qualify ing FEV 1measurement at the screening visit (visit 1)
using the onsite spirometer × 80%. 
Randomization Visit :
Two stability  limits will be re -established at the randomization visit (visit 2) for use during 
the double -blind and open -label treatm ent periods using the following equations: 
Investigational Center Stability  Limits (for use with onsite spirometer at the 
double -blind visits only ): mean FEV 1of the predose pre-bronchodilator qualify ing 
FEV 1measurements (
-30 and -15 min) using the onsite spirometer × 80%
At Home Stability  Limits (for use with the electronic flow meter [home device]): 
mean of the best predose FEV 1measurements on the last 3 day s before randomization 
on the home device × 80%
If a patient falls below any of the above FEV 1stability  limits, an alert will be triggered to the 
patient and investigational center personnel.
Note: If the reschedule icon on the site spirometer is chosen for the screening visit (visit 1) or 
visit 2, and therefore, visit 1 or visit 2 is performe d again, the FEV 1 stability  limit will be 
updated accordingly .  If V1_RETEST on the site spirometer is performed, the stability  limit 
will not be updated.

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 23of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.9.8Spirometry (Part 1 and 2) 
Patients enrolled in Part 1 and Part 2 of the study  will be issued with a n eDiary /electronic 
flow meter to assess their lung function ( FEV 1). FEV 1collection begins at the time of signing 
the ICF, and then continues throughout Part 1 and Part 2, per the randomization scheme.
For Part 1, FEV 1will be measured once dail y: prior to dosing in the morning (if applicable) 
at approximately  the same time each day . On day s of the investigational center visits, 
spirometry  will be performed using the equipment at the investigational center. 
For Part 2, FEV 1will be measured twice dail y at home: upon awakening in the morning 
immediately  prior to dosing with study  medication and at 2 (+2) hours after study  medication 
administration. Three (3) FEV 1measures should be taken at each time point; the highest 
effort will be used.
9.9COPD Exacerbations (Part 1 and Part 2) 
A COPD exacerbation is defined as worsening of symptoms of COPD for at least 
2consecutive day s and classified as mild when patients do not require treatment with 
systemic corticosteroids and/or antibiotics; moderate when treatment with sy stemic 
corticosteroids and/or antibiotics are required; or severe when hospitalization or visit to the 
emergency  care/acute care unit is required. A separate exacerbation is considered when an 
interval of clinical improvement of at least 7 days is observed. 
Any moderate or severe COPD exacerbation occurring during Part 1 will result in withdrawal.
COPD exacerbations will be documented separately from AEs on a COPD exacerbation log 
in the electronic case report form ( eCRF ), unless the exacerbation meets the definition of an 
SAE. I n this instance, the exacerbation will be recorded on both the AE and CO PD 
exacerbation pages of the eCRF. 
Collection of COPD exacerbations will begin at the time of consent and will continue 
through the final visits in Part 1 and Part 2 of the study .COPD exacerbations will be 
captured via patient interview during the onsite or telephone visits.
9.10 COPD Symptom Scores (Part 1 and Part 2)
During Part 1 (commencing at the time of consent) andPart 2 of the study , patients will 
assess and record their COPD symptoms scores once daily in the evening before bedtime 
using the EXACT. 
The EXACT is a 14 -item daily  diary  designed to provide a direct measure of patient -reported 
symptoms of COPD exacerbation. The EXACT Total score is computed across the 14 items 
and has a theoretical range of 0 to 100, with higher values indicating a more s evere condition. 
The total score is used in the determination of exacerbation frequency , severity , and duration 
of exacerbation. 

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 24of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.All 14 items of the EXACT are to be completed by  the patient each evening prior to bedtime, 
reflecting back on their experienc es “today .”
The ER -S: COPD is a derivative instrument of the EXACT designed to address the need for 
standardized daily  diary  to assess respiratory  symptoms in patients with COPD.
The ER -S: COPD is comprised of 11 respiratory  symptom items contained in the 14-item 
EXACT. A dail y Total score (RS -Total score) representing respiratory  symptom severity , 
overall and 3 subscale scores (RS -Breathlessness, RS -Cough and Sputum, and RS -Chest 
Symptoms) can be computed from the E -RS. The daily  RS-Total score is computed by 
summing the raw score assigned to each of the 11 items and has a theoretical range of 0 to 40, 
with higher values indicating more severe respiratory s ymptoms. The same simple 
summation procedure is used for obtaining the 3 daily domain scores of the E -RS: RS -
Breathlessness is the sum of items 7, 8, 9, 10, and 11 (score range 0 -17); RS -Cough and 
Sputum is the sum of items 2, 3, 4 (score range 0 -11); and RS -Chest Sy mptoms is the sum of 
items 1, 5, 6 (score range 0 -12).
The ER -S: COPD (derived from the EXA CT score) will be used to assess disease stability  
throughout the stud y. A baseline score will be obtained from the first available evening 
session after the signing the I CFfor use during the screening and run -in periods and from the 
latest available even ing session before the randomization visit (visit 2) for use during the 
double -blind and open -label treatment periods. If at an y time, there is increase in the ERS -
COPD daily
 RS-Total score of ≥2 from baseline, the eDiary will alert the patient to notify  the 
investigational center personnel to discuss the patient’s current health status. The Investigator 
will need to determine if the patient is able to continue participating in the study as per the
withdrawal criteria. 
9.11 Methods for Handling Dropouts and Mis sing Data
Missing efficacy  data will be handled in the following way s:
For missing serial spirometry  measurements:
Missing data methods will be used provided that at least 9 of the 11 post -dose serial 
spirometry  measurements are available.  Linear interpolation between the 2 adjacent FEV 1
measurements will be used to estimate missing spirometry  measurements occurring between 
2 available measurements. The exception to this would be the unlikely event of missing 
measurements that occur near the peak of the FEV 1-time curve , expected to occur between 
30 min to 2 hours post dose . In these cases the average percentage change from the preceding 
value for patients receiving the same treatment will be used. This makes use of the response 
of other patients to the same treatment. For analy sis, the percentage will be expressed in 
terms of an FEV 1value. 
For missing measurements at the end of the time profile (i .e
., no available FEV 1value after a 
point in time): 
For values at the end of the profile that were missing because rescue medication was 
taken, the minimum observed FEV 1value on that test day, including the predose

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 25of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.value, will be used as the estimate. This is similar to assuming that there would be no 
increase from baseline after the point that rescue medication was required. 
For values at the end of the profile that were missing for reasons unrelated to the 
patient’s response to treatment, the average percentage change from the preceding 
values for patie nts receiving the same treatment will be used. This makes use of the 
response of other patients to the same treatment. For analysis, the percentage will be 
expressed in terms of an FEV 1 value. 
For values at the end of the profile that were missing for unknown reasons, the 
observed minimum FEV 1value on the day  of testing, including the pre-dose value, 
will be used as an estimate. This conservativel y assumes that there would be no 
increase from b aseline after the point that the data were missing. 
Two additional sensitivity  analyses will be performed , where the missing data rules for the 
tail end of the profile will bebased on the following: (a) the AUC calculation will be based 
on the time interval up to the last non -missing time point , and will then be standardized by 
dividing by the length of time for which FEV 1measurements were included (ie. the AUC 
will be a weighted average), and (b) the baseline value will be substituted for the missing 
values.
If a patient contributes data to at least 2 of the crossover legs, data from that patient will be 
included in the analysis as the patient will have provided data for one of the treatment 
comparisons. If a patient completes only 1
 leg of the crossov er, data from the patient will be 
listed but will not be included in summary  statistics or the analysis. There is no reasonable 
basis for imputing data for a completel y missing leg of the crossover.
Anal ysis Population
10.1 Intention -to-Treat
The 
ITT analysis population will adhere as closely  as practicall y possible to the intention -to-
treat (ITT) ideal, and will be based on data from all patients who were randomized, took at 
least one dose of study  medication and contributed sufficient data for at least one efficacy 
endpoint to be calculated. The ITT analy sis population will be the primary  analysis 
population used for the demonstration of the superiority  of the active treatments to placebo. 
In this population, treatment will be assigned based upon the treatment to which patients 
were randomized regardless of which treatment they actuall y received.
10.2 Per Protocol
The Per Protocol (PP) analy sis population will be the primary  analy sis population used for 
the determination of BE between the Test and Reference products .  The PP anal ysis 
population will exclude patients from the ITT population who have major protocol deviations 
in Part 1 of the study  on either the Test treatment day  or the Reference treatment day . 
Patients may  have a major protocol deviation on the Place bo treatment day  and still be 

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 26of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.included in the Per Protocol population that will be used to asses BE although data from the 
Placebo day  will be excluded from the anal ysis.
All patients with a major protocol deviation will be identified before the study bli nd is 
broken, and the removal of a patient from a treatment period will be documented within the 
clinical trial management sy stem’s protocol deviation file. I n addition, individual FEV1 
values from a patient may be removed from their 24 -hour serial curve , including the 
2predose measurements, if they  were the result of poor quality  spirometry  efforts.  In those 
cases, the value will be set to missing and missing value rules applied as described in 
Section 
9.11.
10.3 Safety
The safet y analysis population will include all patients who receive at least one dose of any 
one of the randomized investigational products and for whom data have been collected after 
randomization.
10.4 Part 2 of the Study
All patients who begin treatment during the open -label portion of the study.
10.5 All Subjects
All patients who sign consent form forthe stud y.
10.6 All Randomized Subjects
All patients who arerandomized in the study .
Interim A nalysis
11.1 Objective of the Interim Analysis
A blinded interim look at the data will be made in order to check the assumption about intra -
patient variability  made when estimating sample size with the possibility  of increasing 
sample size, if necessary , to maintain 90% power. The interim look is planned when 150 of 
the planned 240 randomized patients have c ompleted Part 1 of the study .Issues impacting 
the choice of a final sample size will include the estimate of intra -patient variability  and the 
estimate of the ratio of the means demonstrated in the pivotal PK study .The interim anal ysis 
will be conducted by PRA Health Sciences.
11.2 Endpoint for the Interim Analysis
The endpoint for the interim analysis is the baseline -adjusted FEV1 AUC 0-24hon the single-
dose treatment day s.
11.3 Interim Analysis Population
The PP population will be used for the interim analysis.   Patients who have major protocol 
deviations will be excluded from the interim analysis population .

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 27of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.11.4 Sample S ize Re-calculation for the Interim Analysis
The original sample size estimate is based on an assumed intra -patient variability  to which 
sample size estimates are very  sensitive. 
From a review of studies on clinicaltrials.gov, there 
were a number of estimates available of between -patient variability  for baseline -adjusted 
FEV1 AUC 0-24. From the 12 studies reviewed, the mean CV for the variable was 121%. 
Within -patient variability  is generall y much less than between -patient variability . As a 
starting point for the sample size estimation it was assumed that the within -patient variability
would be about 50% of the between -patient variability , or a CV of 60%. A blinded interim 
review of the data is planned to assess if this reduction is obtained. The missing data 
methods outlined in 
section 9.11 will be applied for the interim anal ysis, wi th the following 
exceptions: (1) no imputation would be performed during peak times, and (2) missing data at 
the tail -end of the spirometry  profile would use Last Observation Carried Forward (LOCF) 
methods.
11.4.1 Intra -patient CV Estimation
In order to perform the interim sample size re
-estimation (by  nQuery7 ),the between -subject 
CVand the intra-subject CV need to be estimated using the interim data:
Between -subject CV (CV B)= σ B/ μR
Intra -subject CV (CV I)= σ I/ μR
Where σ Bis between -subject variance, σIis intra -subject variance and μ Ris the Least Square 
Mean(LSMean )ofthe reference ( SPIRIVA) treatment.  
To get estimates for σ B, σIand μ R, a mixed model can be used with a fixed effect for perio d 
and a random effect for patient using the PP population.   The ty pical crossover model fixed 
effects for treatment and sequence are not included because the treatment codes are to remain 
blinded.
The SAS procedure to be used is :
proc mixed data=interim; 
      classusubjid period;
      modelBaseline-adjusted FEV1 AUC 0-24h= period/ solution ;
      randomusubjid;
            run ;
where 
usubjid = patient
period = treatment period

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 28of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.In the SAS output , the covariance (COV) estimate of σ Bwill be called “Usubjid” and σ I will 
be called “Residual”. Normally  we estimate μ Ras the L SMean for the reference ( SPIRIVA) 
treatment, however, since this is a blinded estimation, we could instead use the estimate of 
CV Bfrom the Protocol as: μR= σ B/ 1.21. Then, we use that estimate of μ Rto estimate CV I
= σ I/ μR.
One downside of this approach is that it includes placebo which will almost surely  inflate the 
intra-subject variance (and hence CV I).The effect could be dramatic if the two active 
treatments are efficacious (i.e., much different from placebo) . It should not affect between -
subject variance.
To address this concern , 2 methods will be used to estimate the intra-subject variability  and 
CV:
Use the subject’s AUC values from all 3 treatments to estimate the intra -subject CV. 
This method will provide a liberal (i.e., likely too large) sample size estimate since 
the placebo data will increase the intra -subject CV.
Only  use the data from the two “closest” AUC values from each subject’s data to 
estimate the intra-subject CV. This approach mimics the inclusion of only the two 
active treatments in the sample size re-estimation (i.e., akin to exclud ingplacebo).
This method will produce a conservative (ie, likely too small) sampl e size estimate.
A decision on the sample size re -estimation will be made based on the results from the above 
2 
methods.
11.4.2 Sample S ize Re-calculation
Once intra -patient CV is identified, sample size re -calculation will be performed using 
nQuery 7.0 with the following parameters:
Power = 9 0%
Expected ratio = 0.88 to 1.12
Lower equivalence limit = 0.8
Upper equivalence limit = 1.25
Test significance level alpha (one -sided) = 0.05
CVbetween subjects = 1.21 (assumption from the protocol)
CVwithin subjects = new number calculated from the above mentioned 
model based on the actual interim data
The result s of the 2 new sample size estimates (one based on data from all treatments and the 
other based on the 2 “closest” data values )will be available after using the above parameters. 
The estimate of the ratio of the means demonstrated in the pivotal PK study will help inform
which expected ratio will be used in the final sample size chosen.

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 29of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.11.5 Results of the Interim Analysis
The final interim anal ysis report was dated 01Sep2017, and is attached in 
Appendix 3.
A total of 122 (of the 150) patients had 3 treatment periods with evaluable AUC data, and 
these data were included in the “closest” AUC analy sis. Based on the results, the intra -patient 
CV was 0.3642 and the between -patient CV was 1.210.  The table below summarizes the 
crossover design of two one -sided tests (TOST) for difference or ratio of means :
Closest AUC (N=122)
Protocol Low ratio Ratio=1 High ratio
  Test significance levels, α (one -sided) 0.050 0.050 0.050 0.050
      Lower equivalence limit for µT/ µR, DL 0.800 0.800 0.800 0.800
      Upper equivalence limit for µT/ µR, DU 1.250 1.250 1.250 1.250
  Expected ratio, µT/ µR 1.000 0.880 1.000 1.120
  Coefficient of variation between subjects, CV B 1.210 1.210 1.210 1.210
  Coefficient of variation, intrasubject, CV i 0.600 0.3642 0.3642 0.3642
  Power ( % ) 90 90 90 90
  n total 178 372 78 220
Results obtained from nQuery Advisor® 7.0
Based on the results, sample size estimates range from:
a total of 372 across the six treatment sequences if the expected ratio of test to 
reference is 0.88 
a total of 220 patients across the six treatment sequences if the expected ratio of test 
to reference is 1.12
Assuming an expected ratio of means of 0.90 based on results from the pivotal PK study , an 
estimated 238 per- protocol patients would be needed to demonstrate equivalence between the 
test and reference products.  Therefore, the Sponsor plans to randomize a total of 
approximately  378 patients (instea d of 240 patients specified in the protocol with 
Amendment 1, dated 11May 2017 ), to allow for a potential 30% withdrawal rate or loss from 
the per -protocol population due to protocol deviations.    
Data Review
Final data for analy sis should alway s be clean ed prior to receipt by Clinical Programming. 
The purpose of this section is to indicate the history  of the data and the process used to 
ensure that the data are acceptable for statistical analysis prior to database lock.
12.1 Data Handling and Transfer
PRA prepares and delivers electronic media to each site of their respective subjects’ eCRFs 
and a complete set of subject eCRFs are delivered to each site and Lupin Inc.
The data in the following table will be provi ded by  third -party vendo rs:
Data Type Vendor
Central Lab Eurofins

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 30of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.Central Spirometry ERT
ECG ERT
eDiary ERT
Randomization YPrime
All of the study  data will be provided in SAS®dataset format (SAS version 9.4 or later) and 
converted to Study  Data Tab ulation Model (SDTM) version 1.4 using the Study  Data 
Tabulation Model I mplementat ion Guide (SDTMIG) Version 3.1.4 .  
12.2 Data Screening
Review of 2 pre-freeze TFL dry runsallow for further data screening prior to lock. The pre-
freeze TFL will be discussed with the sponsor in a data review meeting to identify  any final 
data issues and seek corrections prior to database lock. The PRA biostatistician and the 
sponsor must approve database lock.
Statistical Methods
The statistical anal yses will be reported using summary tables, figures, and dat a listings.  The 
summary  tables will be presented separately  for Part 1 and Part 2 of the study . All analyses 
will use SAS version 9.4 or higher.
Continuous variables will be summarized using the number of observations (n), mean, 
standard deviation (std ), median, minimum, and maximum values.  
Unless otherwise noted, categorical variables will be summarized by counts and percentages 
of patients in corresponding categories.  Percentages will be rounded to one decimal place 
except for 100%, which will be display ed without any decimal places, and zero 
counts, for 
which the percentage will be displayed aszero percent .   
Raw data obtained from eCRFs and transferred from third -part vendors and derived data will 
be included in data listings.  
13.1 Subject Disposit ion
The number and percentage of patients with informed consent, screened, screen failure, 
randomization failure, randomized/enrolled, and analysis population will be presented , 
together with the number and percentage of patients who withdraw from the study  
prematurel y and are excluded from a particular analy sis population, and a breakdown of the 
corresponding reasons.  
A tabulation of the number and percentage of patients rand omized
/enrolled at each center 
will also be presented.
13.2 Protocol Deviations
The study  team and the sponsor will conduct on-going reviews of the deviation data 
throughout the stud y. The PPpopulation must be identified prior to database lock.

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 31of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.Protocol deviat ion data will be categorized into one of the following categories:
01-Inclusion/Exclusion/Randomization Criteria
02-Continuation Criteria
03-Spirometry  Evaluation
04-Study  Procedures
05-Study  Drug
06-Out of Window Visits
07-Informed Consent
08-Prohibited / Restricted Medications
09-Other
10-Diary
11-ICH/GCP
Each deviation 
will be further classified as major /minor as defined in the protocol deviation 
guidelines.  A summary  of the number of patients with major deviations will be presented by 
category and treatment for Part 1 and Part 2 of the study  separatel y.  All protocol deviation 
data will be listed.
13.3 Treatments
13.3.1 Extent of Study  Drug Exposure
Summary  statistics for study  drug exposure for Part 1include :
Patients exposed toone or more treatments (1, 2 or 3 )
Patients exposed toa specific treatment (Lupin Tiotropium, SPIRIVA 
HANDIHALER or Placebo )
Summary  statistics for study  drug exposure forPart 2 include:
Days of exposure
13.3.2 Prior and Concomitant Medications
A prior medication is defined as an y medication started and stopped prior to the first 
randomized dose.
A concomitant medication is defined as an
y medication taken on or after the first randomiz ed 
dose regardless of start day.
All medications will be coded using the WHO Drug Dictionary (versi on of September 2016) , 
and Anatomical Therapeutic Chemical (ATC) classification sy stem.
Prior and concomitant medications will be summarized by  ATC classification for Part 1 and 
only concomitant medications will be summarized for Part 2.  All p rior and concomitant 
medications will be listed.

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 32of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.13.4 Demographic and Baseline Characteristics
Patient demographic and baseline characteristics will be summarized by treatment for the 
safet y population , ITT population , PPpopulation , and Part 2 of the study respectively and 
will include summary  statistics for sex, age, age group ( 40 to <65, 65 to <75, ≥ 75), race, 
ethnicity , baseline height (cm), baseline weight (kg) and tobacco u sage.
13.5 Medical H istory
Medical history  will be summarized for Part 1 
only.All medical histor y will be listed. 
13.6 Efficacy Analyses
13.6.1 Primary Variable
The primary  variable is the baseline -adjusted FEV 1AUC 0 -24h on the single- dose treatment 
days. Baseline is defined as the average of the FEV 1values recorded at approximately  
30minutes and 15 minutes before dosing with study medication. 
This crossover study  will follow a Williams design with 6 treatment sequences 
balanced for 
first order carry over effects (see Table 1 ).
A repeated measures crossover model consisting of effects of treatment, period , and sequence 
will be carried out.
The SAS code for the model is as follows:
       proc mixed data=final; 
         classusubjid period treatment sequence ;
         modelBaseline-adjusted FEV1 AUC 0-24h = treatment period sequence / 
solution ddfm=SAT ;
         repeated period /type = un subject = usubjid ;
     lsmeans treatment / alpha=0.05cldiff;  
       run ;
where 
usubjid = patient
period = treatment period
sequence = treatment sequence
13.6.2 Statistical Analysis for the Primary  Variable
13.6.2.1 Establishing Superiority of Test (T) and Reference (R) to Placebo
The hy pothes es planned to be tested for the Superiority analy sis are :
           H01: μT = μP  vs.H11: μT ≠μPand
           H02: μR = μP  vs.H12: μR≠μP

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 33of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.where μ T =mean of b aseline adjust FEV 1AUC 0 -24for the Test G roup and
           μR=mean of baseline adjust FEV 1AUC 0
-24 for the Reference G roup and
           μP=mean of baseline adjust FEV 1AUC 0
-24 forthePlacebo Group
Study sensitivity  will be demonstrated if the Reference (R) product isshown to be 
statistically  superior to Placebo (P) (p <0.05 [two -tailed]). Efficacy  of the Test product will 
be demonstrated if the Test (T
) product is shown to be statistically  superior to Placebo (P) (p 
<0.05 [two -tailed]). For these comparisons, the repeated measures model described in 
Section 13.6.1 will be applied to the I TT population.
13.6.2.2 Establishing Bioequivalence between Test (T) and Reference (R) products
The hy pothes es planned to be tested for the BE analy sis are :
             H0: μT/ μR≤ 0.8 or μT/ μR≥ 1.25
             H1: 0.8 < μT/ μR< 1.25
where μ T=mean of the baseline adjust edFEV 1AUC 0-24 for Test G roup,and
           μR=mean of the baseline adjust edFEV 1AUC 0
-24 for Reference G roup
The anal ysis of the primary  endpoint for BE will be the repeated measures analy sis
(described in the section 13.6.1)performed on the PP Analy sis Set which will include all 
patients in the I TT population except those who had major protocol deviations. 
The extension of Fieller’s theorem to a 3-way crossover will be used as the primary  method 
to assess the bioequivalence of the Test (T) and Reference (R)products.  An analy sis that 
applies Fieller’s theorem only to the data of the Test (T) and Reference (R)products (i.e. 
ignoring data from the placebo treatment) will also be performed as a secondary  method of 
analysis.
We use Fieller’s theorem to create a 100(1 -2α)% CI  for θ= μT/ μR.The CI (θ 1, θ2) will 
include all values of θ for which the above null h ypotheses are rejected.
Fieller’s theor em considers the quantity  G= Y T–θ*Y R, in which Y Tand Y Rare unbiased 
estimates of μTand μ R.Note that E(G)=0. We want to find all values of the parameter θ that 
do not reject H 0: G=0 versus H 1: G≠0.
To do this computationally , we fit the crossover mo del to obtain the estimated means Y Tand 
YR(i.e., the estimated L SMeans). For this study , there are 6 treatment sequences with 3 
periods, which gives the following LSMeans for μ Tand μ R, respectively :
LSmean (Test) = μ + τ T+ 1/3(π 1+ π 2+ π 3) + 1/6*(δ 1+δ2+δ3+δ4+δ5+δ6)           (1)
LSmean (Reference) = μ + τ R+ 1/3(π 1+ π 2+ π 3) + 1/6*(δ 1+δ2+δ3+δ4+δ5+δ6),           (2)

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 34of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.where μ is the intercept, the τ’s are the treatment effects, the π’s are the period effects, and 
the δ’s are the sequence effects from the mixed model. 
The placebo data are included in the 
analysis but the placebo treatment effect, τ P, is not needed in the bioequivalence assessment.
Writing G with equations (1) and (2):
G =  (τ T–θ* τ R) + (1 –θ) [μ + 1/3(π 1+π2+ π 3) + 1/6(δ 1+...+ δ 6)],    (3)
We use various values of θ to test H 0: G=0, and the 100(1 -2α)% C.I. (θ 1, θ2) is defined as 
largest/smallest values which do not reject the two α -level tests for H 0above (Note: This is 
equivalent to a two one -sided tests procedure). The construction o f the estimate statements 
in PROC MI XED will be based on equation (3), and will include data for all sequences, 
treatments and periods (i.e., placebo data will not be deleted).  A sample SAS code for this 
mixed model is shown below, where the estimate stat ements are used to obtain the 90% 
confidence limits:
proc mixed data=<<dataset>> ;
classusubjid treatment period sequence;
modelauc0_24 = treatment period sequence / DDFM=SAT solution ;   
repeated period / type= un subject = usubjid;   
*** Sample estimate statements ***;  
estimate ' 0.720' intercept  0.280treatment  0  -0.72  1
                  period 0.0933 0.0933 0.0933
sequence 0.0467 0.0467 0.0467 0.0467 0.0467 0.0467 /alpha=0.05 upper;
estimate ' 0.721' intercept  0.279treatment  0-0.721  1
period  0.093  0.093  0.093
sequence 0.0465 0.0465 0.0465 0.0465 0.0465 0.0465 /alpha=0.05 upper;
estimate ' 0.722' intercept  0.278treatment  0-0.722  1
period 0.0927 0.0927 0.0927
sequence 0.0463 0.0463 0.0463 0.0463 0.0463 0.0463 /alpha=0.05 upper;
... 
estimate ' 1.369' intercept -0.369treatment  0-1.369  1
period -0.123-0.123-0.123
sequence -0.061-0.061-0.061-0.061-0.061-0.061/alpha=0.05 lower;
estimate ' 1.370' intercept -0.370treatment  0  -1.37  1
period -0.123-0.123-0.123
sequence -0.062-0.062-0.062-0.062-0.062-0.062/alpha=0.05 lower;
*** end of sample estimate statements ***;  
lsmeans treatment / alpha=0.05cl diff
cov;   
run;
The Satterthwaite (DDFM=SAT) option provides the usual within -subject error degrees of 
freedom (DF) in the case of no missing data, and provides an adjustment to the error DF in 
the case of missing data.  I n either case, the error degrees of freedom will be quite large given 
the sample size of this trial so that the test statistic will have a near normal distribution.
Bioequivalence (BE) will be declared if the estimated 90% CI, ( θ1,θ2) is entirely contained 
within the required BE limits of 0.80 to 1.25.
In addition to the 3 -treatment effect model above, a sep arate anal ysis will be done using a 2 -
treatment approach, where Placebo (P) will be removed from the data.  The construction of 

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 35of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.the 90% C.I. (θ 1, θ2) will use the same approach as defined above, with only the 2 active 
treatments needed in the estimate statement.
The above approach is equivalent to a closed form solution created b y Fieller’s theorem 
which only  requires the Test (T) and Reference (R)LSMean estimates and their 
variances/covariances, and the critical value of the test statistic (T -test or Z-test).
13.6.2.3 Time to Maximum Bronchodilator Response
The time to ma ximum bronchodilator response ( tmax) is defined as the time post -dosing of the 
maximum FEV1 value for a patient.  This will be summarized using descriptive statistics by 
treatment and sequence .
13.6.3 Subgroup A nalyses
No subgroup anal yses are planned for this study .
13.6.4 Multiplicity
In this clinical trial, t he comparisons of interest are: 
1.The superiorit y comparison between Lupin Tiotropium Bromide Inhalation 
Powder, 18 mcg (T) and Placebo (P) 
2.The superiorit y comparison between SPI RIVA HANDIHALER, 18 mcg (R) and 
Placebo (P) 
3. The bioequivalence comparison between Lupin Tiotropium Bromide Inhalation 
Powder, 18 mcg (T) and SPI RIVA HANDIHALER, 18 mcg (R) 
As all 3 of these comparisons must be succes sfully  achieved in order to demonstrate BE, no 
adjustment for multiplicity  is required. The order of testing will be according to the list above.
13.6.5 Pooling of Sites
Pooling of sites is not planned for this study.
13.7 Safety Analyses
Safety  analyses will be summarized by treatment for the safet y population as defined in
Section 10.3 for Part 1 and Part 2separatel y
.Summary  statistics (number of subjects, mean, 
standard deviation, median, minimum, and maximum) will be included for continuous 
variables. Summarizations of categorical variables will be presented in tabular form (number 
of subjects and percentages). Safety of drug regimen will be assessed for adverse events, 
serious adverse 
events (SAEs), COPD exacerbations, vital signs, physical examinations, 
HEENT and chest exami nations, ECG recordings, SABA (albuterol/salbutamol MDI) and 
concomitant medication use . 
Listings of all safety  measurements will be provided.

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 36of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.13.7.1 Adverse Events
The adverse event (AE) data will be summarized separately  for Part 1 and Part 2 of the study
by treatment and total .
Summaries of treatment -emergent adverse events (TEAEs), including the 
number and 
percentage of events reported, the number and percentage of patients reporting at least one 
AE, at least one severe AE, at least one treatment -related AE, at least one SAE, at least one 
treatment -related SAE, at least one non-SAE, at least one AE leading to withdrawal, and at 
least one AE resulting in death will be presented by treatment . Treatment -emergent adverse 
events are those which first occur or increase in severit y or relationship to study  drug after 
the first dose of stud y drug after randomization . 
A breakdown of the number and percentage of patients reporting each adverse event, 
categorized by System Organ Class (SOC ) andPreferred Term (PT) according to MedDRA 
20.0, will be presented by treatment. Note that counting will be by patient not event and 
patients are onl y counted once within each SOC or PT.
A further tabulation of these data, categorized by  relationship to study  drug, will be presented. 
Relationship to study  drug is categorized as Related/Not Related as recorded on the CRF.
A summary  of events reported, categorized by severit y (Mild, Moderate and Severe), will 
also be provided. Patients with multiple events within a particular body  system or preferred 
term will be counted under the category of their most severe event within that SOC or PT.
A summary  of SAEs, AEs leading to discontinuation and AEs leading to death will be 
provided b y treatment, study part and total, grouped by SOC and PT.
Adverse events (A Es) that occur before randomization will be summarized separately  and 
will be listed. Those patients will not be part of the safet y population. 
All adverse events (including non-treatment -emergent events) recorded on the CRF will be 
listed.
13.7.1.1 AE Summary fo r Part 1 of the Study
In Part 1, the blinded, single dose crossover part of the study, AEs will be tabulated b y the 
following periods: 
•The double- blinded s tudy treatment period ( Lupin Tiotropium Inhalation 
Powder , SPI RIVA HANDIHALER and Placebo )
•during washout 
• during follow- up 
Adverse events (AEs) occurring after a stud y treatment during a treatment day and the day 
immediately  after the treatment will be assigned to the relevant stud y treatment group. AEs 
occurring between the treatment day s will be assigned to the washout period.
13.7.1.2 AE Summary for P art 2 of the Study
Adverse events (AEs) will be tabulated separately  for Part 2 of the study  by the following periods: 

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 37of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.• T he open -label study treatment period, which starts after the first dose of Part 2
•During follow -up 
13.7.2 Laboratory  Data
Standard clinical laboratory  tests including hematology , chemistry , urinalysis and 
immunochemistry (
serum pregnancy )will be performed as indicated in Table 2Schedule of 
Events using a central laboratory  as indicated in the study  procedures manual.
All laboratory  data (including re -tests) provided by  the ce ntral laboratory  will be listed.
13.7.3 Vital Signs
Vital signs, inc luding blood pressure, heart rate, respiratory  rate and body  temperature, will 
be collected at the screening visit (visit 1) and all subsequent investigational center visits. 
Descriptive statistics for vital signs at screening and at treatment visits (visi ts 2 through 4 or 
ET for Part 1 and visits 7, 9, and 10 or ET for Part 2) will be provided. 
For Part 1, the double -blind period, summary  statistic s will be provided by  treatment. 
Summary  statistics will be provided separatel y for Part 2, the open label e xtension. 
13.7.4 Physical Examinations
For Part 1, ph ysical examination findings at screening (visit 1) and visit 4 or ET will be 
summarized for any clinically significant findings. Significant chan ges from screening 
(visit 1) to the end of the double -blind period will be summarized. Changes from screening 
(visit 1) to the end of the double -blind period will be presented in 3 by
 3 shift tables, where 
the responses are normal, abnormal but clinicall y non-significant, or abnormal an d clinically  
significant. Each examination area, eg, skin, abdominal, will have a separate table. Some 
patients may  require 2PEs before treatment starts. If they  do, the first one is the 
prescreening value and the one at visit 1 is the screening value . Prescreening results will be
listed only .
For Part 2 of the study  (open -label extension), findings at visit 10 or ET will be summarized 
for an y clinically significant findings and significant chan ges from screening (visit 1) to the 
end of the open -label e xtension using the 3 by 3 shift tables described above.
13.7.5 HEENT, Chest Examination, and Electrocardiograms (ECG) 
For Part 1, during the double -blind period, abbreviated phy sical examination findings 
(HEENT and chest examinations) will be summarized for an y clinicall y significant findings 
and si gnificant changes from Visit 2 .  ECG results will be summarized by  visit, and changes 
in overall clinical interpretation will be summarized.
For Part 2 of the study  (open label extension), findings will be summarized for an y clinically 
significant findings and si gnificant changes from Visit 2 . 

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 38of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.HEENT and chest examination findings will be su mmarized by  four 3 by 3 shift tables where 
the shift is from visit 2 to each of the 4 visits during treatment, 2visits in Part 1 and 2 visits 
in Part 2.
Electrocardiograph y (ECG) findings will be summarized by  four 3 by 3 shift tables where the 
shift is from screening (visit 1) to each of the 4visits during treatment, 2visits in Part 1 and 2
visits in Part 2.
13.7.6 COP D Exacerbations
COPD exacerbations will be summarized and/or listed separatel y for Part 1 and Part 2 of the 
study .
13.7.7 Safety  Spirometry
Patients will be issued an eDiary /electronic flow meter to measure FEV 1for monitoring 
disease stability . 
For Part 1, FEV 1will be measured once dail y: prior to dosing in the morning at 
approximately  the same time each day . 
For Part 2, FEV 1will be measured twice dail y at home: upon awakening in the morning 
immediately  prior to dosing with study  medication and at 2 (+2) hour s after study  medication 
administration. 
Values for each patient will be listed.
13.7.8 EXACT/ER -S Scores
EXACT scores will be recorded in the patient’s eDiary once daily each evening before 
bedtime. Values of the ER -S COPD for each patient will be listed.
13.7.9 Albuterol/Salbutamol Usage
Albuterol/Salbutamol usage will be summarized and/or listed by treatment and study  period .
13.7.10 Urine/Serum Pregnancy  Test
Urine/Serum pregnancy  test results will be listed.
13.7.11 Urine Drug Screen
Urine
drug screen results will be listed.
In addition, drug accountability , smoking restriction, DPI training and In-Check training will 
also be listed. 

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 39of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.13.7.12 Inhaler Robustness ( Part 1 and Part 2)
13.7.12.1 Ruggedness of LUPINHALER during In -Patient Use
Patients will be instructed to report an y problems that they experience with their 
LUP INHALER during the open -label extension. The number and percentage of patients who 
reported at least one issue with the LUPINHALER will be provided separately  for Part 1 and 
Part 2. 
Additionally , a summary of the individual issues will be provided. The summary will 
describe the issue in the detail provided by the patient. These will also be summarized 
according to the following categories: 
Misuse (impact, moisture, other) and
Issues identified (hard to open
cover/mouthpiece, hard to insert capsule, hard to 
pierce capsule, capsule not rattling with inhalation, hard to remove capsule, hard to 
close mouthpiece/cover, COPD worsening/seems ineffective, other)
13.7.12.2 In Vitro Pharmaceutical Performance
In vitro pharmace utical performance of 100 inhalers post 72 days of in-patient use will be 
assessed. The data resulting from the in vitro evaluation of the pharmaceutical performance 
will be presented in a separate report.
Validation
PRA's goal is to ensure that each TFL delivery  is submitted to the highest level of quality . 
Our quality  control procedures will be documented separatel y in the study  specific quality  
control plan. 
References
Global I nitiative for Chronic Obstructive Lung Disease (GOLD). Global strategy  for th e 
diagnosis, management, and prevention of COPD. Updated 2016. http://www.goldcopd.org 
Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic 
obstructive pulmonary  disease. Cochrane database of systematic reviews 2005:CD002876 
Chey ne L, Irvin -Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic 
obstructive pulmonary  disease. Cochrane Database Sy st Rev 2013 Sep 16;9:CD00955
Mathers CD, Loncar D. Projections of global mortality  and burden of disease from 2002 to 
2030. PL oS Med 2006;3:e442 
Van den Boom G, van Schay ck CP, van Mollen MP, et al. Active detection of chronic 
obstructive pulmonary  disease and asthma in the general population. Results and economic 
consequences of the DIMCA program. Am J Respir Crit Care Med 1998;158:1730 -8.

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 40of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.Appendix 1 Glossary  of A bbreviations
Glossary of Abbreviations:
Abbreviation Definition
AE Adverse Event
ATC Anatomic Therapeutic Classification
AUC 0-24Area Under The Curve From Time Zero To 24 Hours 
Post-dose
BE Bioequivalence
BMI Body Mass Index
CI Confidence Interval 
CV Coefficient Of Variation 
COPD Chronic Obstructive Pulmonary Disease
CRF Case Report Form
DPI Dry Powder Inhaler
ECG Electrocardiogram
ER-S Evaluating Respiratory Symptoms
ET End Of Treatment
EXACT Exacerbations Of Chronic Pulmonary Disease Tool
FEV1 Forced Expiratory Volume In The First Second
GCP Good Clinical Practice
HEENT Head, Ears, Eyes, Nose, And Throat
ICH International Conference On Harmonization
ICS Inhaled Corticosteroid
ID Identification
IRT Interactive Response Technology 
ITT Intention -To-Treat
LABA Long -Acting Beta Agonist
LAMA Long -Acting Anti -
Muscarinic Agent
MDI Metered Dose Inhaler 
MedDRA Medical Dictionary For Regulatory Activities
P Placebo
PDV Protocol Deviation
PK Pharmacokinetic
PP Per Protocol

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 41of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.PRO Patient Reported Outcome 
PT Preferred Term
R Reference
SABA Short -Acting Bronchodilator 
SAMA Short -Acting Anti -Muscarinic Agent
SAP Statistical Analysis Plan
SAE Serious Adverse Event
SDTM Study Data Tabulation Model 
SDTMIG Study Data Tabulation Model Implementation Guide
SI International System 
SOC System Organ Class 
T Test
TEAE Treatment Emergent Adverse Event 
WHO World Health Organization

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 42of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.Appendix 2: EXACT DA ILY DIA RY
Instructions: Please complete your diary  every  evening, just before you go to bed. As you 
answer the following questions, please select the option that best describes your 
experience.
The eDiary will be programmed to display  your ER-S: COPD daily  respiratory  symptoms 
(RS) Total score. A baseline score will be obtained from the first available evening 
session after the screening visit (visit 1) for use during the screening and run-in periods 
and from the latest available evening session before the randomization visit (visit 2) for 
use during the double -blind and open -label treatment periods.  If at any time, there is 
increas e in the daily  RS Total score of≥2 from baseline, th e eDiary will alert y ou to notify 
investigational center personnel to discuss y our current health status.
1.
Did y our chest feel congested
today ?Not at all
Slightly
Moderatel y
Severel y
Extremely
2. How often did you cough today ?Not at all
Rarel y
Occasionall y
Frequently
Almost constantly
3. How much mucus (phlegm) did
you bring up when coughing today ?None at all
A little
Some
A great deal
A very  great deal
4. How difficult was it to bring up
mucus (phlegm) today ?Not at all
Slightly
Moderatel y
Quite a bit
Extremely
5. Did y ou have chest discomfort
today ?Not at all
Slight
Moderate
Severe
Extreme
6. Did y our chest feel tight today ? Not at all

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 43of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.Slightly
Moderatel y
Severel y
Extremely
7. Were y ou breathless today ?Not at all
Slightly
Moderatel y
Severel y
Extremely
8. Describe how breathless y ou
were today :Unaware of breathlessness
Breathless during strenuous activity
Breathless during light activity
Breathless when washing or dressing
Present when resting
9. Were y ou short of breath today
when performing y our usual
personal care activities like washing
or dressing?Not at all
Slightly
Moderatel y
Severel y
Extremely
Too breathless to do these
10. Were y ou short of breath today
when performing y our usual indoor
activities like cleaning or household
work?Not at all
Slightly
Moderatel y
Severel y
Extremely
Too breathless to do these
11. Were y ou short of breath today
when performing y our usual
activities outside the home such as
yard work or errands?Not at all
Slightly
Moderatel y
Severel y
Extremely
Too breathless to do these
12. Were y ou tired or weak today ?Not at all
Slightly
Moderatel y
Severel y

Statistical Analysis Plan
Version Date: Final 08Feb2018
Sponsor: Lupin Inc.
Protocol no: TB -DPI-301
Page 44of 49
Strictly Confidential.  © 2004 -2015, .  All rights reserved.Extremely
13. L ast night, was y our sleep
disturbed?Not at all
Slightly
Moderatel y
Severel y
Extremely
14. How scared or worried were you
about y our lung problems today ?Not at all
Slightly
Moderatel y
Severel y
Extremely
Copy rightEXACT© 2013, Evidera, I nc. All rights reserved. 
EXACT version 1.1 -English (universal) 9/9/2009
*The EXACT instrument and scoring program are owned b y Evidera. The questions
listed above may  be display ed in another format as per the formal licensing agreement
with the eDiary vendor.
